ANP reading comparing it to BLT and saying its cheap which I agree with
http://seekingalpha.com/instablog/15774362-lemmema2/2766093-the-long-case-for-antisense-therapeutics
"Valuation
The market cap of antisense therapeutics is currently 23M $. Compared to companies in the same field such as Benitec ($BNIKF) with a market cap of 150M $ and the progression of the pipeline of antisense therapeutics, this company is significantly undervalued. Two compounds (ATL1102 and ATL1103) have already successful passed the Phase I trail and are currently in Phase 2 (ATL1102 is used for multiple indications and has only been in Phase 2 for Multiple Sclerosis). Furthermore, ATL1102 is in preclinical development for treatment of Asthma and ATL1101 is currently also in preclinical development. Benitec has a broader portfolio and has partnered with better know companies, however, Benitec is still in Phase 1 trials compared to Antisense Therapeutics. Thus my investment thesis is to consider this company fairly valued at a Market cap around 75M $, which is a conservative approach. Consequently I am expecting the price per share to increase to ~0.40AUD $ by the end of 2014
Given the partnership with one of the leaders in the field of RNA therapeutics ($ISIS) this company has significant upside potential over the next year(s) and I personally consider this as a long term investment."
- Forums
- ASX - Day Trading
- daytrading march 20 morning
daytrading march 20 morning, page-5
-
- There are more pages in this discussion • 108 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Featured News
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online